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Edited by Frances ShannonAbstract The diﬀusion properties of EGFP-hGRa and mutants
C421G, A458T and I566 in living cells were analyzed. The wild
type and mutants C421G and A458T translocated from the cyto-
plasm to the nucleus after addition of Dex; however, the Brown-
ian motions of the proteins were diﬀerent. The diﬀusion constant
of wild-type GRa after addition of Dex slowed to 15.6% of that
in the absence of Dex, whereas those of A458T and C421G slo-
wed to 34.8% and 61.7%, respectively. This is the ﬁrst report
that dimer formation is less important than the binding activity
of GRa to GRE in the living cell.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Understanding the interactions and dynamic properties of
biomolecules and biomolecular networks in living cells is of
central importance in life science. Direct observation of the
actions of transcription factors in the living cell can provide
important insights into gene regulatory mechanisms. We ana-
lyzed the diﬀusion of green ﬂuorescence protein fused human
glucocorticoid receptor a (EGFP-hGRa) before and after
addition of ligands in the nuclei of living cells using ﬂuores-
cence correlation spectroscopy (FCS).
The glucocorticoid receptor (GR) is a transcriptional regula-
tory protein that controls broad physiological gene networks,
and has pathological eﬀects in a range of diseases; therefore
the protein oﬀers an excellent target for therapeutic interven-
tion [1,2]. GR is associated with several proteins in the absence
of ligands in the cytoplasm. The humans GR receptor can be
found in two isoforms GRa, and GRb. GRa consists of 777
amino acids, binds hormones and activates glucorticoid-
responsive genes. Upon ligand binding, GRa is driven intoAbbreviations: FCS, ﬂuorescence correlation spectroscopy; FAF, ﬂu-
orescence autocorrelation function; EGFP, enhanced green ﬂuorescent
protein; Dex, dexamethasone; LBD, ligand binding domain; DBD,
DNA binding domain; GR, glucocorticoid receptor; GRE, glucocor-
ticoid response element
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doi:10.1016/j.febslet.2006.12.038the nucleus, and regulates transactivation by association with
speciﬁc genomic glucocorticoid response elements (GRE).
Various functional domains and many cofactors of GRa
have been identiﬁed by biochemical and molecular biological
methods [3], and dynamics of GRa in the living cell has been
analyzed using ﬂuorescence recovery after photobleaching
(FRAP) [4–6].
Large studies of FRAP using GFP-tagged proteins have
been employed to understand diﬀusion kinetics of nuclear fac-
tors. However, even the sensitivity of conventional ﬂuores-
cence techniques, including FRAP expanded to the single
molecule level, can detect only slow dynamics [7].
FCS has been used to analyze the microenvironment of the
cell membrane [8], endoplasmic reticulum [9] and nucleus and
nucleolus [10], though the changes in the diﬀusion (Brownian)
motion of ﬂuorophores could not be detected by FRAP because
of rapid movement. We have detected a slow-moving compo-
nent of EGFP-hGRa in the nucleus with the addition of dexa-
methasone (Dex). To elucidate this slow component, we
constructed three hGRa mutants: EGFP-hGRa/C421G
(C421G) which cannot associate with GRE [11], EGFP-
hGRa/A458T (A458T), with no dimerization ability [12], and
EGFP-hGRa/I566 (I566), in which the ligand binding domain
(LBD)was deleted to reduce associationwith some cofactors [1].2. Materials and methods
2.1. Chemicals and plasmids
Dexamethasone (Dex) and RU486 were purchased from Sigma (St.
Louis, MO, USA). These chemicals were used as ethanol solutions.
Plasmids encoding the hGRa fused with green ﬂuorescent protein
(pCMX-hGRa-GFP) were kindly provided by Dr. H. Tanaka [13]
and Dr. Y. Nomura [14]. To obtain brighter ﬂuorescence, pEGFP-
hGRa was constructed by PCR ampliﬁcation of hGRa fragments
and ligation into pEGFP-C1 (Clontech, Palo Alto, CA, USA).
EGFP-hGRa/I566 (I566) and EGFP-hGRa/A458T (A458T) plasmids
were constructed by PCR ampliﬁcation, EGFP-hGRa/C421G
(C421G) plasmid was constructed by a two step PCR procedure [15],
with primers containing mutations using pEGFP-hGRa as a template.
After puriﬁcation of PCR products, the digested fragments inserted
into pEGFP-hGRa were cut with restriction enzymes. The pairs of
primers and restriction enzymes for I566, A458T and C421G are
shown below:
I566; forward: 50-AATGATTGCATCATCGATAAAATTCGAAGA-3 0,
reverse: 5 0-CACTTGGATCCCTCATAACATGTTGAGCGTA-
GTC-3 0,




restriction enzymes: Esp3I and ClaI.blished by Elsevier B.V. All rights reserved.
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Fig. 1. LSM images and normalized FAFs in a HeLa cell expressing
EGFP. (A) A HeLa cell expressing EGFP was imaged before (left) and
60 min after (right) addition of Dex to 100 nM. The scale bar
represents 10 lm. (B) FAFs were acquired in PBS buﬀer (cross) or at
the nucleus (square) and cytoplasm (triangle) in HeLa cells expressing
EGFP. FCS measurement performed before (open symbols) and
60 min after (closed symbols) addition of 100 nM Dex (C) or RU486.
390 S. Mikuni et al. / FEBS Letters 581 (2007) 389–393C421G; forward-1: 5 0-GGGTCCCCAGGTAAAGAGACGAA-3 0,
reverse-1: 5 0-CAGAGCACACCAGGCCGAGTTTGGGAGG-30,
and
forward-2: 5 0-ACCTCCCAAACTCGGCCTGGTGTGCTCTG-3 0,
reverse-2: 5 0-CAGAGGTTTCTTGTGAGACTCCTGTAGTG-3 0
restriction enzymes: Esp3I and ClaI.
All of the above PCRs were performed using KOD-Plus- (TOYOBO,
Tokyo, Japan) according to the manufacturer’s instructions.
2.2. Transient transfection
HeLa cells were transfected using the lipofection reagent FuGENE 6
(Roche Molecular Biochemicals, Mannheim, Germany) with 0.1 lg/
well pEGFP-C1, pEGFP-hGRa, pEGFP-hGRa/I566, pEGFP-
hGRa/A458T or pEGFP-hGRa/C421G according to the manufac-
turer’s instructions.
2.3. FCS measurement and analysis
FCS measurement was performed with a LSM510-ConfoCor2 com-
bination system (Carl Zeiss, Jena, Germany) before and every 10 min
after addition of 100 nM of the indicated ligands. Each set of FCS
measurements was carried out ﬁve times with a duration of 15 s. Fluo-
rescence autocorrelation functions (FAFs, G(s)) were acquired and
ﬁtted with the FCS Fit program by one-, two-, or three-component
models as follows:
GðsÞ ¼ hIðtÞihIðt þ sÞihIðtÞi2









p þ 1 ð1Þ
where Ftriplet is the average fraction of triplet state molecules, striplet is
the triplet relaxation time, Fi and si are the fraction and diﬀusion time
of component i, respectively, N is the number of ﬂuorescence molecules
in the detection volume element deﬁned by radius w0 and length 2z0,
and s is the structural parameter representing the ratio, s = z0/w0. In
this paper, the ﬂuorescence autocorrelation function was shown as
normalized by N for comparisons of s.
Normalized GðsÞ ¼ NðGðsÞ  1Þ ð2Þ
Diﬀusion constants of samples were obtained from the ratio with the
diﬀusion constant of R6G and diﬀusion time sR6G and ssample [8].3. Results and discussion
3.1. Mobility of EGFP in the living cell
As shown in Fig. 1A, EGFP was distributed without distinc-
tion in the cytoplasm and nucleus even if Dex was added.
Similar FAFs were obtained for the nucleus and cytoplasm
(Fig. 1B). Most FAFs in the nucleus and cytoplasm could be
ﬁtted with a one-component model and the averages of the
diﬀusion constants were calculated to be 20.4 ± 3.2 lm2/s
and 19.3 ± 0.9 lm2/s, respectively. This indicated that EGFP
did not interact with any proteins or diﬀuse as free-moving
molecules whether in the nucleus or cytoplasm. Moreover, this
mobility of EGFP was not aﬀected by addition of ligands
(Fig. 1B, C). FAFs in PBS buﬀer solution could be ﬁtted with
the one-component model and the average diﬀusion constant
was calculated to be 72.8 ± 2.8 lm2/s (Fig. 1B), the same as
in previous reports [8].3.2. The eﬀect of Dex on the localization and diﬀusion of EGFP-
hGRa
To observe the localization of EGFP-hGRa in HeLa cells,
confocal LSM images were taken before and after additionof Dex. EGFP-hGRa was mainly localized in the cytoplasm
in the absence of Dex. However, the subcellular localization
of EGFP-hGRa was changed to the nucleus by exposure to
Dex, a transactivation agonist, within 30 min (Fig. 2A). We
also measured FAFs of EGFP-hGRa in the nuclei of the living
cells. As shown in Fig. 2B, normalized FAFs were clearly
shifted to the right by the presence of Dex in the nucleus. This
shift indicated that a slow-moving EGFP-hGRa appeared.
Under this concentration of Dex, the slow-moving fraction
reached a plateau in 20 min (data not shown). On the other
hand, FAFs obtained from the cytoplasm did not diﬀer in
the presence and absence of Dex (Fig. 2C).
Most FAFs in the nuclei could be ﬁtted with a two-compo-
nent model. The average diﬀusion constants and fractions are
summarized in Table 1, which shows that the fractions of each
component were not much changed (Table 1, F1 and F2). On
the other hand, addition of Dex reduced the diﬀusion cons-
tants of the second component to 15.6% of that in the absence
of Dex (Fig. 7). This result could indicate that this slow-
moving component originated from the formation of a com-
plex with transcription cofactors and/or interaction with
DNA of the activated hGRa. It is noted that the fast compo-
nent of wild-type GRa decreased in the presence of Dex, this
may indicate that an initial complex of GRa and a cofactor
could be detected.
Dex (-) Dex ( +)
Cytoplasm 









































Fig. 2. LSM images and normalized FAFs in HeLa cells expressing
EGFP-hGRa. (A) HeLa cells expressing EGFP-hGRa were imaged
using confocal LSM, before (left) and 60 min after (right) addition of
Dex to 100 nM. The scale bar represents 10 lm. FCS measurement
performed (B) in the nuclei and (C) cytoplasm of HeLa cells expressing
EGFP-hGRa, before (open squares) and 60 min after (closed squares)
addition of Dex. The normalized FAFs were shifted to the right by
addition of Dex at the nucleus.
AF-1 DBD AF-2 LBDEGFP









Fig. 3. Schematic structures of wild-type EGFP-hGRa and mutants.
hGRa protein contains three major domains. The N-terminal trans-
activation domain consists of the activation function domain, which is
required for transcriptional enhancement. The central DNA binding
domain contains two zinc ﬁnger regions critical for receptor dimer-
ization and target DNA binding. The C-terminal ligand binding
domain serves as a binding site for coactivators, and contains nuclear
localization signals. AF-1, activation function 1; DBD, DNA binding
domain; AF-2, activation function 2; LBD, ligand binding domain;
NLS, nuclear localization signal.
S. Mikuni et al. / FEBS Letters 581 (2007) 389–393 3913.3. The diﬀerence between mutants and the wild-type hGRa
To identify what part of hGRa changed the slow-moving
diﬀusion in the presence of Dex, we constructed three mutants,
as shown in Fig. 3.
As shown in Fig. 4A, B, C421G and A458T were translo-
cated from the cytoplasm to the nucleus by exposure to DexTable 1
Diﬀusion constants and fractions of wild-type hGRa and mutants in the nu
Ligand n First
DC1 (lm2/s)
Wild type Dex () 23 14.30 ± 4.87
Dex (+) 23 8.70 ± 2.59*
C421G Dex () 25 15.08 ± 5.25
Dex (+) 23 13.71 ± 4.93
A458T Dex () 23 16.54 ± 6.39
Dex (+) 24 12.96 ± 3.43
D566 Dex () 22 13.76 ± 2.46
Dex (+) 27 13.31 ± 2.56
Wild type RU486 (+) 24 8.89 ± 3.93
Diﬀusion constants (DC), fraction (F), number (n) of cells for FCS measureme
(Dex ()), to the presence of Dex (+) or RU486 (+).
*Signiﬁcantly diﬀerent (P < 0.0001).
aThis value was compared with the wild type in the absence of Dex.like the wild-type hGRa. Interestingly, there was no diﬀerence
in the LSM images between the wild type and mutants; how-
ever, normalized FAFs of C421G and A458T (Fig. 5A, B) were
diﬀerent compared with the wild type of hGRa in the presence
of Dex. Moreover, the eﬀect of Dex on the shift of FAFs was
in order of the wild type, A458T and C421G. On the other
hand, the I566 mutant was localized in the nucleus indepen-
dently of Dex stimulation, and normalized FAFs did not
change (Fig. 6B). FAFs of mutants in the nuclei were analyzed
by two-component ﬁtting, and the average diﬀusion constants
and fractions are summarized in Table 1. The ﬁrst (fast mov-
ing) component of each mutant was not signiﬁcantly aﬀected
by Dex. On the other hand, the diﬀusion constant of the sec-
ond (slow moving) component decreased after addition of
Dex (Fig. 7). Dex addition slowed the second components of
A458T and C421G to 34.8% and 61.7% of those in the absence
of Dex, respectively. A diﬀerent diﬀusional property was
observed in our experiment between A458T and C421G,
although both mutants did not have transcriptional activity
[11,12]. This result may indicate that slow-moving hGRa was
aﬀected by DNA binding rather than dimerization and could
be an indicator of its transcriptional activity because A458T
was more aﬀected by Dex addition than C421G was. More-
over, although I566 localized in the nucleus, the diﬀusion con-cleus
Second
F1 (%) DC2 (lm2/s) (Pdc (%)) F2 (%)
60.7 1.60 ± 0.44 39.3
63.9 0.25 ± 0.09* (15.6) 36.1
67.5 1.49 ± 0.48 32.5
60.0 0.92 ± 0.36* (61.7) 40.0
62.9 1.61 ± 0.64 37.1
55.2 0.56 ± 0.11* (34.8) 44.8
59.4 1.07 ± 0.17 40.6
62.9 0.96 ± 0.33 (60.0)a 37.1
64.8 0.86 ± 0.37* (53.4)a 35.2
nts in nucleus and percentage (Pdc) of diﬀusion constant in the absence
Fig. 4. Subcellular localization of EGFP-hGRa mutants. HeLa cells
expressing (A) EGFP-hGRa/C421G, (B) EGFP-hGRa/A458T, (C)
EGFP-hGRa/I566 were imaged before (left) and 60 min after (right)
addition of Dex to 100 nM. The scale bar represents 10 lm. C421G
and A458T were translocated to the nucleus by stimulation with Dex.
I566 was localized in the nucleus before addition of Dex.
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Fig. 5. Typical FAFs of EGFP-hGRa mutants in the nuclei before
and after addition of Dex. FCS measurement performed in nuclei of
HeLa cells expressing (A) EGFP-hGRa/C421G, (B) EGFP-hGRa/
A458T, (C) EGFP-hGRa/I566 before (open squares) and 60 min after
(closed squares) addition of Dex. All normalized FAFs diﬀered from
the wild type in the presence of Dex in the nucleus (see Fig. 2B).
392 S. Mikuni et al. / FEBS Letters 581 (2007) 389–393stant was only 60.0% of that of the wild type in the absence of
Dex. This result also indicated that LBD had an important ef-
fect on slow-moving hGRa in the nucleus.
3.4. The diﬀerence between the eﬀects of agonists and
antagonists on hGRa
We also examined the eﬀect of RU486, a transactivational
antagonist of hGRa [16], in the nucleus. As shown in
Fig. 6A, EGFP-hGRa was translocated to the nucleus by sti-
mulation with RU486 as well as Dex. FAFs obtained in the
nucleus before and after addition of RU486 (Fig. 6B) were
analyzed by two-component ﬁtting and the average diﬀusion
constants and fractions are summarized in Table 1. It was con-
ﬁrmed that RU486 reduced the diﬀusion constant of wild type
to 53.4% of that in the absence of Dex, although hGRa was
translocated to the nucleus as well as with Dex (Fig. 2). This
result demonstrated that agonist and antagonist were distin-
guished by diﬀusion analysis using FCS. The fast component
of wild type in the presence of RU486 was also reduced. This
result might relate to the result of wild type in the presence of
Dex and may indicate that initial complex and/or unstable
complex of GRa and cofactor in the presence of RU486 could
be detected. However further study is needed to clarify this
phenomena.4. Conclusion
The activity of mutant hGRa in the nucleus can be deter-
mined according to diﬀerences of dynamic properties such as
diﬀusion and translocation, which are obtained by FCS and
LSM, respectively. However, our results suggested that the
transactivation of hGRa was related more to the mobility of
the protein than to its translocation from the cytoplasm tothe nucleus. We found that tethering of the diﬀusion was re-
lated to the transactivational process, such as DNA binding,
dimerization and formation of complex of hGRa. Moreover,
our results also suggested that dimerization of hGRa in the nu-
cleus could act as a supportive factor to form the hGRa–GRE
complex. Consequently, it is concluded that the biomolecule
activity of hGRa with chemicals such as inhibitors, agonists
and antagonists in cell compartments such as the nucleus can
be determined through mobility analysis by FCS. However,
the target binding site of GRa is mainly GRE in chromosomes;
many associated proteins whose molecular size is not so large
have also been identiﬁed in the cytoplasm. The interaction be-
tween such associated proteins and hGRa will be analyzed by
advanced ﬂuorescent techniques such as ﬂuorescence cross-
correlation spectroscopy (FCCS) since FCS can only detect
large changes in molecular mass interactions such as chromo-
somes and hGRa. On the other hand, FCCS can detect pro-
tein–protein interactions in living cells when spectrally
distinguishable ﬂuorophores are available for each associated
protein and GRa [17]. In this study, we conﬁrmed that the
combination of FCS and LSM is a feasible technique to clarify
the highly dynamic mechanisms of biomolecules in living cells.
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Fig. 6. The eﬀect of RU486 on the localization and the mobility of
EGFP-hGRa. (A) HeLa cells expressing EGFP-hGRa were imaged
before (left) and 60 min after (right) addition of RU486 to 100 nM.
The scale bar represents 10 lm. (B) FCS measurement performed in
the nuclei of HeLa cells expressing EGFP-hGRa, before (open
squares) and 60 min after (closed squares) addition of RU486. The











Fig. 7. Summary of the diﬀusion constants of second components. The
white, black and gray bars indicate diﬀusion constants before addition
of ligands, and after addition of Dex and RU486, respectively. After
addition of Dex, the diﬀusion constants of the wild type, C421G and
A458T decreased to 15.6%, 61.7%, and 34.8% of those in the absence
of Dex, respectively. The diﬀusion constant of I566 decreased to 60.0%
of that of the wild type in the absence of Dex. RU486 reduced the
diﬀusion to 53.4% of that of the wild type in the absence.
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